Search results
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters via AOL· 3 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity
FierceBiotech· 3 days agoPfizer and Flagship Pioneering have settled on the first target for their billion-dollar,...
Pfizer Inc. (NYSE:PFE) Shares Sold by Waddell & Associates LLC
ETF DAILY NEWS· 6 days agoWaddell & Associates LLC reduced its position in Pfizer Inc. (NYSE:PFE – Free Report) by 40.0% in the 4th quarter, according to its most recent disclosure with the Securities ...
Billionaires Are Buying These 2 Ultra-High-Yield Dividend Stocks Hand Over Fist. Are They Smart Buys...
The Motley Fool via AOL· 5 days agoThey buy dividend-paying stocks because they know that companies committed to returning a portion of earnings to shareholders tend to outperform ones that don't. In the first three months of ...
Sarepta Jumps After Rival Gene Therapy From Pfizer Flops
Investor's Business Daily· 2 days agoThe news gives Sarepta Therapeutics (SRPT) an edge heading to June 21, when the Food and Drug Administration will decide whether to fully approve Elevidys for patients with the muscle-wasting ...
Bridgeway Capital Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoBridgeway Capital Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 26.0% during the 4th quarter, according to its most recent 13F filing ...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 3 days agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin ...
Weik Capital Management Sells 10,839 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 7 days agoWeik Capital Management decreased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 26.3% in the 4th quarter, according to the company in its most recent filing with ...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 3 days agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
FOX Business· 7 days agoA 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long...
